Learn More
510 Background: GT had phase II safety and efficacy in MBC after anthracyclines, so it was compared to T in a phase III study of frontline therapy. Accrual goals were met in 4/02 and at initial(More)
This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour(More)